Clinical Trial Update: Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update examining the combination of anlotinib with sintilimab as second-line treatment or beyond for small cell lung cancer in Phase 2 and Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Changzhou Cancer Hospital of Soochow University | Conditions: Small Cell Lung Cancer | Phase 2, Phase 3 | Status: UNKNOWN